You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Periodic fever syndromes
Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes
in adults, adolescents and children aged 2 years and older:
Cryopyrin-associated periodic syndromes
Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults
and children aged 2 years or older including:
Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU)
Muckle-Wells Syndrome (MWS)
Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile
Neurological, Cutaneous, Articular Syndrome (CINCA).
Tumour necrosis factor receptor associated periodic syndrome (TRAPS)
Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated
periodic syndrome (TRAPS).
Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)
Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate
kinase deficiency (MKD).
Familial Mediterranean fever (FMF)
Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be
given in combination with colchicine, if appropriate.
Ilaris is also indicated for the treatment of:
Systemic Juvenile Idiopathic Arthritis (sJIA)
Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in
patients aged 2 years or older.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Periodic fever syndromes
Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes
in adults, adolescents and children aged 2 years and older:
Cryopyrin-associated periodic syndromes
Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults
and children aged 2 years or older including:
Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU)
Muckle-Wells Syndrome (MWS)
Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile
Neurological, Cutaneous, Articular Syndrome (CINCA).
Tumour necrosis factor receptor associated periodic syndrome (TRAPS)
Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated
periodic syndrome (TRAPS).
Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)
Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate
kinase deficiency (MKD).
Familial Mediterranean fever (FMF)
Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be
given in combination with colchicine, if appropriate.
Ilaris is also indicated for the treatment of:
Systemic Juvenile Idiopathic Arthritis (sJIA)
Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in
patients aged 2 years or older.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Periodic fever syndromes
Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes
in adults, adolescents and children aged 2 years and older:
Cryopyrin-associated periodic syndromes
Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults
and children aged 2 years or older including:
Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU)
Muckle-Wells Syndrome (MWS)
Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile
Neurological, Cutaneous, Articular Syndrome (CINCA).
Tumour necrosis factor receptor associated periodic syndrome (TRAPS)
Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated
periodic syndrome (TRAPS).
Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)
Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate
kinase deficiency (MKD).
Familial Mediterranean fever (FMF)
Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be
given in combination with colchicine, if appropriate.
Ilaris is also indicated for the treatment of:
Systemic Juvenile Idiopathic Arthritis (sJIA)
Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in
patients aged 2 years or older.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
